It includes the review of studies using molecular, genetic, cellular, biochemical, pharmacological, genomic, proteomic, and physiological approaches to define normal and pathological processes. MIM evaluates study proposals ranging from in vitro models of simulated ischemia in isolated cells to whole animal models to human studies.
The List of Reviewers lists all present, whether permanent or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.
The membership panel is a list of chartered members only.
- Mechanisms of ischemia/reperfusion tissue injury: myocardial stunning, infarction, hibernation, early post-ischemic cardiac remodeling.
- Mechanisms of myocardial cell death (apoptosis/necrosis) and autophagy.
- Cardioprotection, cardiac repair and regeneration: cardiac repair/regeneration following ischemic injury, cardiac bioengineering, including strategies to support stem cell therapy
- Cellular and molecular mechanisms that govern the biology of stem cells in ischemic heart disease
- Control of coronary blood flow: post-ischemic coronary vascular abnormalities, coronary endothelial function, angiogenesis, collateral circulation
- Signal transduction mechanisms of myocardial ischemia/reperfusion injury: preconditioning, postconditioning;
- Metabolism and energetics in acquired heart disease: Impact of diet, obesity or systemic metabolic disorders on myocardial metabolism mitochondrial function, or the response to ischemia/reperfusion.
- Novel cardiac imaging methods to assess myocardial metabolism, injury, and fibrosis
Shared Interests and Overlaps
There are shared interests between MIM and Cardiovascular Differentiation and Development (CDD). Applications that focus on stem cells and their differentiation in cell therapy approaches to the repair and regeneration of ischemic myocardium may be reviewed in MIM. Likewise, applications that focus on stem cells in diabetes or other metabolic disorder settings may be reviewed in MIM. Applications that focus on the signaling in differentiation of embryonic and adult stem cells into cardiomyocytes, endothelium, smooth muscle and other components of the cardiovascular system may be reviewed in CDD.
There are shared interests between MIM and Cardiac Contractility, Hypertrophy, and Failure (CCHF). Applications that focus on molecular and cellular mechanisms underlying cardiac hypertrophy or remodeling and heart failure in the context of diabetes and settings of metabolic disorders may be reviewed in MIM. Applications that focus on mitochondrial (dys)function in genetic cardiomyopathies or other cardiovascular diseases may be reviewed in MIM. Applications with a dominant remodeling and/or contractility component may be reviewed in CCHF. Similarly, applications that focus on cardiac repair as it relates to contractility and fibrotic remodeling may be reviewed in CCHF.
There are shared interests between MIM and Biomaterials and Biointerfaces Study Section (BMBI). Applications that focus on cell and tissue engineering approaches to repair and regeneration of ischemic myocardium may be reviewed in MIM. Likewise, applications with a focus on molecular and cellular interactions with bioactive materials in the post-ischemic myocardium, especially in settings of metabolic disease, may be reviewed in MIM. Applications with a dominant component focused on new biomaterials and fabrication techniques for tissue engineering and biomaterial scaffolds to support cells, stem cell differentiation and therapy may be reviewed in BMBI.